Arsanis raises $20m to finance anti-infection MAb 'cocktail'
This article was originally published in Scrip
Executive Summary
Austrian biotech Arsanis has raised $20m in a series B round, which it plans to use to progress its lead monoclonal antibody program against Staphylococcus aureus, ASN-100.
You may also be interested in...
IPO Update: Biopharma Firms Give Thanks For Receptive US Investors
Six biopharma firms went public in the US in November during the three weeks leading up to Thanksgiving, raising $539.5m and counting. With 39 IPOs so far this year, 2017 has had nine more first-time offerings than 2016 with five more weeks to go.
WuXi eases CAR-T manufacturing burden with new US plant
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
NICE lifts Entyvio restrictions after Takeda offers discount
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.